Journal of the American Academy of Dermatology · 2026
Cardiometabolic Associations of Dermatological Treatments. Part I: Systemic Therapies.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Maggie H, Garshick Michael S, Gelfand Joel M, LaRocca Cecilia A, Lo Sicco Kristen I, Mehta Nehal N, Lipner Shari R
Аннотация
Systemic treatments for common dermatological conditions, including psoriasis, hair loss, and onychomycosis, may be associated with cardiometabolic toxicities or protective effects. Increased awareness of associations between these dermatological treatments and cardiovascular and metabolic health (termed collectively cardiometabolic health) is needed for proactive management of patients with increased risk of cardiovascular diseases. Preventive medications may be indicated with certain treatments. Multidisciplinary efforts between dermatologists, cardiologists, endocrinologists, rheumatologists, oncologists, and primary care physicians may help reduce the risk of major adverse cardiovascular events. In Part I of this two-part continuing medical education series, we provide updates regarding the potential impact on development or worsening of cardiometabolic diseases from traditional systemic treatments, including retinoids/rexinoids, anthracyclines, antifungals, oral minoxidil, methotrexate, ultraviolet phototherapy, and colchicine. We also describe mechanisms of actions impacting cardiometabolic diseases, as well as provide practical recommendations for workup and monitoring in dermatological patients.